The abstract is read at the publisher; the summary is JClub's.
Derazantinib 300 mg once daily produced clinically meaningful responses in previously treated advanced intrahepatic cholangiocarcinoma with FGFR2 fusions, with ORR 22.3% and median PFS 8.1 months.
- Why it matters: FGFR2-driven iCCA after chemotherapy has limited options, and the study addresses the need for an effective, tolerable targeted therapy for patients with specific FGFR2 aberrations.
- What they did: In an open-label, non-controlled Phase 2 trial, patients with advanced iCCA (≥1 prior chemotherapy) received derazantinib until progression or unacceptable toxicity, with efficacy assessed by central RECIST v1.1 review.
- The result: In the FGFR2 fusion/rearrangement subgroup, DCR was 75.7% and median duration of response was 6.5 months, with no Grade 4 or 5 drug-related events reported.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.